Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sjögren's Syndrome (SS)
Conditions
Interventions
VIB4920
Placebo
Locations
62
United States
Research Site
Fullerton, California, United States
Research site
Upland, California, United States
Research Site
Lawrenceville, Georgia, United States
Research Site
Kansas City, Kansas, United States
Research Site
Baltimore, Maryland, United States
Research Site
Wheaton, Maryland, United States
Start Date
December 9, 2019
Primary Completion Date
September 1, 2022
Completion Date
March 10, 2023
Last Updated
April 30, 2025
NCT07361094
NCT06203457
NCT07212322
NCT07185139
NCT06484855
NCT05817669
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions